Sunday 11 October 2026 Export all ABBV data to Excel Powerpack

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

276.47 4.05 +1.49%
Market cap
$481.4B
P/E
78.1×
Fwd P/E
27.8×
Dividend yield
3.10%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

175.41 96.82 107.14 71.08
P/S ratio
6.87 6.61 6.13 6.91
P/FCF ratio
20.81 22.69 19.27 24.45
P/Operating CF
58.31 77.46 100.54 129.56
P/B ratio
0.00 0.00 0.00 0.00
EV/Sales
7.92 7.63 7.14 7.91
EV/EBITDA
20.90 19.39 18.52 19.91
EV/FCF
24.01 26.18 22.44 27.97
Current Ratio
0.72 0.67 0.80 0.81
Net Debt/EBITDA
13.10 9.53 10.71 7.73
Debt/Equity
(26.45) (20.91) (11.02) (12.03)
Earnings Yield
0.57% 1.03% 0.93% 1.41%
Free Cash Flow Yield
4.81% 4.41% 5.19% 4.09%
Free Cash Flow per Share
3.76 2.76 2.01 1.76
Book value per Share
(1.47) (1.82) (3.74) (3.33)
Free Cash Flow
6,643.00 4,889.00 3,564.00 3,114.00
EV/EBIT
52.28 30.94 29.25 30.20
Other line items

Show all line items

Columns are period end dates